OMEGA-3-ACID ETHYL ESTERS - omega-3-acid ethyl esters capsule, liquid filled

Quality Care Products, LLC

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use omega-3-acid ethyl esters capsules, USP safely and effectively. See full prescribing information for omega-3- acid ethyl esters capsules, USP.
OMEGA-3-ACID ETHYL ESTERS Capsules, USP for oral use Initial U.S. Approval: 2004
 INDICATIONS AND USAGE Omega-3-acid ethyl esters, USP is a combination of ethyl esters of omega 3 fatty acids, principally eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). (1) Limitations of Use: The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. (1)
 The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. (1)
DOSAGE AND ADMINISTRATION
 The daily dose of omega-3-acid ethyl esters is 4 grams per day taken as a single 4-gram dose (4 capsules) or as two 2-gram doses (2 capsules given twice daily). (2) Patients should be advised to swallow omega-3-acid ethyl esters capsules whole. Do not break open, crush, dissolve, or chew omega-3-acid ethyl esters capsules. (2)
DOSAGE FORMS AND STRENGTHS
Capsules: 1 gram (3)
Omega-3-acid ethyl esters capsules are contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to omega-3-acid ethyl esters capsules or any of its components. (4)
WARNINGS AND PRECAUTIONS
 In patients with hepatic impairment, monitor ALT and AST levels periodically during therapy. (5.1) Omega-3-acid ethyl esters capsules may increase levels of low-density lipoprotein (LDL). Monitor LDL levels periodically during therapy. (5.1) Use with caution in patients with known hypersensitivity to fish and/or shellfish. (5.2)
• There is a possible association between omega-3-acid ethyl esters and more frequent recurrences of symptomatic atrial fibrillation or flutter in patients with paroxysmal or persistent atrial fibrillation, particularly within the first months of initiating therapy. (5.3)
The most common adverse reactions (incidence >3% and greater than placebo) were eructation, dyspepsia, and taste perversion. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Omerce 2 exide may prolong blooding time. Deticate taking emerce 2 exide thy lectors concules and an
Omega-3-acids may prolong bleeding time. Patients taking omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e.g., anti-platelet agents) should be monitored periodically. (7.1)
 • Pregnancy: Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. (8.1)
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 8/2020

FULL PRESCRIBING INFORMATION: CONTENTS* **1 INDICATIONS AND USAGE** 2 DOSAGE AND ADMINISTRATION **3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS** 5 WARNINGS AND PRECAUTIONS 5.1 Monitoring: Laboratory Tests 5.2 Fish Allergy 5.3 Recurrent Atrial Fibrillation (AF) or Flutter **6 ADVERSE REACTIONS** 6.1 Clinical Trials Experience 6.2 Postmarketing Experience **7 DRUG INTERACTIONS** 7.1 Anticoagulants or Other Drugs Affecting Coagulation **8 USE IN SPECIFIC POPULATIONS** 8.1 Pregnancy 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use **9 DRUG ABUSE AND DEPENDENCE 11 DESCRIPTION** 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.3 Pharmacokinetics **13 NONCLINICAL TOXICOLOGY** 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility **14 CLINICAL STUDIES** 14.1 Severe Hypertriglyceridemia **16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION**

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (greater than or equal to 500 mg per dL) hypertriglyceridemia (HTG).

Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP.

Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy.

Limitations of Use:

The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined.

The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined.

2 DOSAGE AND ADMINISTRATION

- Assess triglyceride levels carefully before initiating therapy. Identify other causes (e.g., diabetes mellitus, hypothyroidism, medications) of high triglyceride levels and manage as appropriate [see Indications and Usage (1)].
- Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, and should continue this diet during treatment with omega-3-acid ethyl esters capsules. In clinical studies, omega-3-acid ethyl esters capsules were administered with meals.

The daily dose of omega-3-acid ethyl esters capsules is 4 grams per day. The daily dose may be taken as a single 4-gram dose (4 capsules) or as two 2-gram doses (2 capsules given twice daily).

Patients should be advised to swallow omega-3-acid ethyl esters capsules whole. Do not break open, crush, dissolve, or chew omega-3-acid ethyl esters capsules.

3 DOSAGE FORMS AND STRENGTHS

Omega-3-acid ethyl esters capsules, USP are supplied as 1-gram transparent, soft gelatin capsules filled with light yellowish oil printed with white ink (Logo "APO900").

4 CONTRAINDICATIONS

Omega-3-acid ethyl esters capsules are contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to omega-3-acid ethyl esters capsules or any of its components.

5 WARNINGS AND PRECAUTIONS

5.1 Monitoring: Laboratory Tests

In patients with hepatic impairment, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels should be monitored periodically during therapy with

omega-3-acid ethyl esters capsules. In some patients, increases in ALT levels without a concurrent increase in AST levels were observed.

In some patients, omega-3-acid ethyl esters capsule increases low-density lipoprotein cholesterol (LDL-C) levels. LDL-C levels should be monitored periodically during therapy with omega-3-acid ethyl esters.

Laboratory studies should be performed periodically to measure the patient's TG levels during therapy with omega-3-acid ethyl esters.

5.2 Fish Allergy

Omega-3-acid ethyl esters capsules contain ethyl esters of omega-3 fatty acids (EPA and DHA) obtained from the oil of several fish sources. It is not known whether patients with allergies to fish and/or shellfish, are at increased risk of an allergic reaction to omega-3-acid ethyl esters capsules. Omega-3-acid ethyl esters capsules should be used with caution in patients with known hypersensitivity to fish and/or shellfish.

5.3 Recurrent Atrial Fibrillation (AF) or Flutter

In a double-blind, placebo-controlled trial of 663 subjects with symptomatic paroxysmal AF (n=542) or persistent AF (n=121), recurrent AF or flutter was observed in subjects randomized to omega-3-acid ethyl esters who received 8 grams per day for 7 days and 4 grams per day thereafter for 23 weeks at a higher rate relative to placebo. Subjects in this trial had median baseline triglycerides of 127 mg per dL, had no substantial structural heart disease, were taking no anti-arrhythmic therapy (rate control permitted), and were in normal sinus rhythm at baseline.

At 24 weeks, in the paroxysmal AF stratum, there were 129 (47%) first recurrent symptomatic AF or flutter events on placebo and 141 (53%) on omega-3-acid ethyl esters (primary endpoint, HR 1.19; 95% CI: 0.93, 1.35). In the persistent AF stratum, there were 19 (35%) events on placebo and 34 (52%) events on omega-3-acid ethyl esters (HR 1.63; 95% CI: 0.91, 2.18). For both strata combined, the HR was 1.25; 95% CI: 1.00, 1.40. Although the clinical significance of these results is uncertain, there is a possible association between omega-3-acid ethyl esters and more frequent recurrences of symptomatic atrial fibrillation or flutter in patients with paroxysmal or persistent atrial fibrillation, particularly within the first 2 to 3 months of initiating therapy.

Omega-3-acid ethyl esters capsules are not indicated for the treatment of AF or flutter.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse reactions reported in at least 3% of subjects treated with omega-3-acid ethyl esters capsules and at a greater rate than placebo based on pooled data across 23 clinical trials are listed in Table 1.

Table 1. Adverse Reactions Occurring at

Incidence ≥3% and Greater than Placebo in Clinical Trials of omega-3-acid ethyl esters capsules

Adverse Reactions *	ethyl		Placebo (n = 370)		
	n	%	n	%	
Eructation	29	4	5	1	
Dyspepsia	22	3	6	2	
Taste perversion	27	4	1	≤1	

* Trials included subjects with HTG and severe HTG.

Additional adverse reactions from clinical trials are listed below:

Digestive System: Constipation, gastrointestinal disorder and vomiting.

Metabolic and Nutritional Disorders: Increased ALT and increased AST.

Skin: Pruritus and rash.

6.2 Postmarketing Experience

In addition to adverse reactions reported from clinical trials, the events described below have been identified during post-approval use of omega-3-acid ethyl esters capsules. Because these events are reported voluntarily from a population of unknown size, it is not possible to reliably estimate their frequency or to always establish a causal relationship to drug exposure.

The following events have been reported: anaphylactic reaction, hemorrhagic diathesis, urticaria.

7 DRUG INTERACTIONS

7.1 Anticoagulants or Other Drugs Affecting Coagulation

Some trials with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these trials has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical trials have not been done to thoroughly examine the effect of omega-3-acid ethyl esters and concomitant anticoagulants. Patients receiving treatment with omega-3-acid ethyl esters and an anticoagulant or other drug affecting coagulation (e.g., anti-platelet agents) should be monitored periodically.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category C: There are no adequate and well-controlled studies in pregnant

women. It is unknown whether omega-3-acid ethyl esters capsules can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. Omega-3acid ethyl esters capsules should be used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus.

Animal Data:

Omega-3-acid ethyl esters have been shown to have an embryocidal effect in pregnant rats when given in doses resulting in exposures 7 times the recommended human dose of 4 grams per day based on a body surface area comparison.

In female rats given oral gavage doses of 100, 600, and 2,000 mg per kg per day beginning 2 weeks prior to mating and continuing through gestation and lactation, no adverse effects were observed in the high-dose group (5 times human systemic exposure following an oral dose of 4 grams per day based on body surface area comparison).

In pregnant rats given oral gavage doses of 1,000, 3,000, and 6,000 mg per kg per day from gestation day 6 through 15, no adverse effects were observed (14 times human systemic exposure following an oral dose of 4 grams per day based on a body surface area comparison).

In pregnant rats given oral gavage doses of 100, 600, and 2,000 mg per kg per day from gestation day 14 through lactation day 21, no adverse effects were seen at 2,000 mg per kg per day (5 times the human systemic exposure following an oral dose of 4 grams per day based on a body surface area comparison). However, decreased live births (20% reduction) and decreased survival to postnatal day 4 (40% reduction) were observed in a dose-ranging study using higher doses of 3,000 mg per kg per day (7 times the human systemic exposure following an oral dose of 4 grams per day based on a body surface area comparison).

In pregnant rabbits given oral gavage doses of 375, 750, and 1,500 mg per kg per day from gestation day 7 through 19, no findings were observed in the fetuses in groups given 375 mg/kg/day (2 times human systemic exposure following an oral dose of 4 grams per day based on a body surface area comparison). However, at higher doses, evidence of maternal toxicity was observed (4 times human systemic exposure following an oral dose of 4 grams per day based on a body surface area comparison).

8.3 Nursing Mothers

Studies with omega-3-acid ethyl esters have demonstrated excretion in human milk. The effect of this excretion on the infant of a nursing mother is unknown; caution should be exercised when omega-3-acid ethyl esters capsules are administered to a nursing mother. An animal study in lactating rats given oral gavage ¹⁴C-ethyl EPA demonstrated that drug levels were 6 to 14 times higher in milk than in plasma.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use

A limited number of subjects older than 65 years were enrolled in the clinical trials of omega-3-acid ethyl esters capsules. Safety and efficacy findings in subjects older than

60 years did not appear to differ from those of subjects younger than 60 years.


9 DRUG ABUSE AND DEPENDENCE

Omega-3-acid ethyl esters capsules do not have any known drug abuse or withdrawal effects.


11 DESCRIPTION

Omega-3-acid ethyl esters capsules, USP, a lipid-regulating agent, are supplied as a liquid-filled gel capsule for oral administration. Each 1-gram capsule of omega-3-acid ethyl esters capsules, USP contains at least 900 mg of the ethyl esters of omega-3 fatty acids sourced from fish oils. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).

The molecular formula of EPA ethyl ester is C22H34O2, and the molecular weight of EPA ethyl ester is 330.51. The structural formula of EPA ethyl ester is:



The molecular formula of DHA ethyl ester is C24H36O2, and the molecular weight of DHA ethyl ester is 356.55. The structural formula of DHA ethyl ester is:



Omega-3-acid ethyl esters capsules, USP also contain the following inactive ingredients: 4 mg α -tocopherol (in a carrier of soybean oil), and gelatin, glycerin, purified water, and white ink (components of the capsule shell). The capsule imprinting ink contains ammonium hydroxide, propylene glycol, shellac glaze, simethicone and titanium dioxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism of action of omega-3-acid ethyl esters is not completely understood. Potential mechanisms of action include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal β -oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. Omega-3-acid ethyl esters may reduce the synthesis of triglycerides in the liver because EPA and DHA are poor substrates for the enzymes responsible for TG synthesis, and EPA and DHA inhibit esterification of other fatty acids.

12.3 Pharmacokinetics

<u>Absorption</u>

In healthy volunteers and in subjects with hypertriglyceridemia, EPA and DHA were absorbed when administered as ethyl esters orally. Omega-3-acids administered as ethyl esters induced significant, dose-dependent increases in serum phospholipid EPA content, though increases in DHA content were less marked and not dose-dependent when administered as ethyl esters.

Specific Populations:

Age: Uptake of EPA and DHA into serum phospholipids in subjects treated with omega-3-acid ethyl esters was independent of age (younger than 49 years versus 49 years and older).

Male and Female Patients: Females tended to have more uptake of EPA into serum phospholipids than males. The clinical significance of this is unknown.

Pediatric Patients: Pharmacokinetics of omega-3-acid ethyl esters have not been studied.

Patients with Renal or Hepatic Impairment: Omega-3-acid ethyl esters has not been studied in patients with renal or hepatic impairment.

Drug Interaction Studies:

Simvastatin: In a 14-day trial of 24 healthy adult subjects, daily coadministration of simvastatin 80 mg with omega-3-acid ethyl esters 4 grams did not affect the extent (AUC) or rate (C_{max}) of exposure to simvastatin or the major active metabolite, beta-hydroxy simvastatin at steady state.

Atorvastatin: In a 14-day trial of 50 healthy adult subjects, daily coadministration of atorvastatin 80 mg with omega-3-acid ethyl esters 4 grams did not affect AUC or C_{max} of exposure to atorvastatin, 2-hydroxyatorvastatin, or 4-hydroxyatorvastatin at steady state.

Rosuvastatin: In a 14-day trial of 48 healthy adult subjects, daily coadministration of rosuvastatin 40 mg with omega-3-acid ethyl esters 4 grams did not affect AUC or C_{max} of exposure to rosuvastatin at steady state.

In vitro studies using human liver microsomes indicated that clinically significant cytochrome P450-mediated inhibition by EPA/DHA combinations are not expected in humans.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In a rat carcinogenicity study with oral gavage doses of 100, 600, and 2,000 mg per kg per day, males were treated with omega-3-acid ethyl esters for 101 weeks and females for 89 weeks without an increased incidence of tumors (up to 5 times human systemic exposures following an oral dose of 4 grams per day based on a body surface area comparison). Standard lifetime carcinogenicity bioassays were not conducted in mice.

Omega-3-acid ethyl esters were not mutagenic or clastogenic with or without metabolic

activation in the bacterial mutagenesis (Ames) test with Salmonella typhimurium and Escherichia coli or in the chromosomal aberration assay in Chinese hamster V79 lung cells or human lymphocytes. Omega-3-acid ethyl esters were negative in the in vivo mouse micronucleus assay.

In a rat fertility study with oral gavage doses of 100, 600, and 2,000 mg per kg per day, males were treated for 10 weeks prior to mating and females were treated for 2 weeks prior to and throughout mating, gestation, and lactation. No adverse effect on fertility was observed at 2,000 mg/kg/day (5 times human systemic exposure following an oral dose of 4 grams/day based on a body surface area comparison).

14 CLINICAL STUDIES

14.1 Severe Hypertriglyceridemia

The effects of omega-3-acid ethyl esters 4 grams per day were assessed in 2 randomized, placebo-controlled, double-blind, parallel-group trials of 84 adult subjects (42 on omega-3-acid ethyl esters, 42 on placebo) with very high triglyceride levels. Subjects whose baseline triglyceride levels were between 500 and 2,000 mg per dL were enrolled in these 2 trials of 6 and 16 weeks' duration. The median triglyceride and LDL-C levels in these subjects were 792 mg per dL and 100 mg per dL, respectively. Median high-density lipoprotein cholesterol (HDL-C) level was 23.0 mg per dL.

The changes in the major lipoprotein lipid parameters for the groups receiving omega-3acid ethyl esters or placebo are shown in Table 2.

Parameter	Omega-3-acid ethyl esters n = 42		Pla n :	Difference	
	BL	% Change	BL	% Change	_
TG	816	-44.9	788	+6.7	-51.6
Non-HDL-C	271	-13.8	292	-3.6	-10.2
ТС	296	-9.7	314	-1.7	-8.0
VLDL-C	175	-41.7	175	-0.9	-40.8
HDL-C	22	+9.1	24	0.0	+9.1
LDL-C	89	+44.5	108	-4.8	+49.3

Table 2. Median Baseline and Percent Change from Baseline in Lipid Parameters in Subjects With Severe Hypertriglyceridemia (≥500 mg/dL)

BL = Baseline (mg per dL); % Change = Median Percent Change from Baseline; Difference = omega-3-acid ethyl esters Median % Change - Placebo Median % Change.

VLDL-C = Very-lowdensity lipoprotein (VLDL) cholesterol.

Omega-3-acid ethyl esters 4 grams per day reduced median TG, VLDL-C, and non-HDL-C levels and increased median HDL-C from baseline relative to placebo. Treatment with omega-3-acid ethyl esters to reduce very high TG levels may result in elevations in LDL-C and non-HDL-C in some individuals. Patients should be monitored to ensure that the LDL-C level does not increase excessively.

The effect of omega-3-acid ethyl esters on the risk of pancreatitis has not been

determined.

The effect of omega-3-acid ethyl esters on cardiovascular mortality and morbidity has not been determined.

16 HOW SUPPLIED/STORAGE AND HANDLING

Omega-3-acid ethyl esters capsules, USP are supplied as 1-gram transparent, oblong soft gelatin capsules with light yellowish oil printed with white ink (Logo "APO900").

They are supplied as follows:

55700-873-01

Store in tight, light-resistant containers at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from light. Do not freeze. Keep out of reach of children.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Information for Patients:

- Omega-3-acid ethyl esters capsules should be used with caution in patients with known sensitivity or allergy to fish and/or shellfish [see *Warnings and Precautions* (5.2)].
- Advise patients that use of lipid-regulating agents does not reduce the importance of adhering to diet [see *Dosage and Administration (2)*].
- Advise patients not to alter omega-3-acid ethyl esters capsules in any way and to ingest intact capsules only [see *Dosage and Administration (2)*].
- Instruct patients to take omega-3-acid ethyl esters capsules as prescribed. If a dose is missed, advise patients to take it as soon as they remember. However, if they miss one day of omega-3-acid ethyl esters capsules, they should not double the dose when they take it.

APOTEX INC.

Omega-3-Acid Ethyl Esters Capsules, USP1 gram

Manufactured in Canada for:

Apotex Corp.

Weston, FL. 33326 USA

Revision: 5

Revised: April 2019

Patient Information

Omega-3-Acid Ethyl Esters

(oh-may-ga-as-id-eth-il-es-ters)

Capsules, USP

What areomega-3-acid ethyl esters capsules?

Omega-3-acid ethyl esters capsules are a prescription medicine used along with a low fat and low cholesterol diet to lower very high triglyceride (fat) levels in adults.

It is not known if omega-3-acid ethyl esters capsules change your risk of having inflammation of your pancreas (pancreatitis).

It is not known if omega-3-acid ethyl esters capsules prevent you from having a heart attack or stroke.

It is not known if omega-3-acid ethyl esters capsules are safe and effective in children.

Who should not take omega-3-acid ethyl esters capsules?

Do not take omega-3-acid ethyl esters capsules if you are allergic to omega-3acid ethyl esters or any of the ingredients in omega-3-acid ethyl esters capsules. See the end of this leaflet for a complete list of ingredients in omega-3-acid ethyl esters capsules.

Before taking omega-3-acid ethyl esters capsules, tell your healthcare provider about all of your medical conditions, including if you:

- have diabetes.
- have a low thyroid problem (hypothyroidism).
- have a liver problem.
- have a pancreas problem.
- have a certain heart rhythm problem called atrial fibrillation or flutter.
- are allergic to fish or shellfish. It is not known if people who are allergic to fish or shellfish are also allergic to omega-3-acid ethyl esters capsules.
- are pregnant or plan to become pregnant. It is not known if omega-3-acid ethyl esters capsules will harm your unborn baby.
- are breastfeeding or plan to breastfeed. Omega-3-acid ethyl esters can pass into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take omega-3-acid ethyl esters.

Tell your healthcare provider about all the medicines you take, including prescription and over-the counter medicines, vitamins, and herbal supplements.

Omega-3-acid ethyl esters capsules can interact with certain other medicines that you are taking. Using omega-3-acid ethyl esters capsules with medicines that affect blood clotting (anticoagulants or blood thinners) may cause serious side effects.

How should I take omega-3-acid ethyl esters capsules?

- Take omega-3-acid ethyl esters capsules exactly as your doctor tells you to take it.
- You should not take more than 4 capsules of omega-3-acid ethyl esters capsules each day. Either take all 4 capsules at one time, or 2 capsules two times a day.
- Do not change your dose or stop omega-3-acid ethyl esters capsules without talking to your healthcare provider.
- Take omega-3-acid ethyl esters capsules with food.
- Take omega-3-acid ethyl esters capsules whole. Do not break, crush, dissolve, or chew omega-3-acid ethyl esters capsules before swallowing. If you cannot swallow

omega-3-acid ethyl esters capsules whole, tell your doctor. You may need a different medicine.

- If you miss a dose of omega-3-acid ethyl esters capsules, take the missed dose as soon as you remember. If you miss one day of omega-3-acid ethyl esters capsules, do not double your dose the next time you take it.
- Your healthcare provider may start you on a cholesterol-lowering diet before giving you omega-3-acid ethyl esters capsules. Stay on this diet while taking omega-3-acid ethyl esters capsules. Stay on this diet while taking omega-3-acid ethyl esters capsules.
- Your healthcare provider should do blood tests to check your triglyceride, bad cholesterol (LDL-C) and liver function (ALT and AST) levels while you take omega-3acid ethyl esters capsules.

What are the possible side effects of omega-3-acid ethyl esters capsules?

Omega-3-acid ethyl esters capsules may cause serious side effects, including:

- **changes in certain blood tests**. Omega-3-acid ethyl esters capsules may cause an increase in the results of blood tests used to check your liver function and your bad cholesterol levels.
- increased risk of a heart rhythm problem in people who have a heart rhythm problem. Omega-3-acid ethyl esters capsules may cause an increase in the frequency of a heart rhythm problem (atrial fibrillation or flutter), especially in the first few months of taking LOVAZA, if you already have a heart rhythm problem.

The most common side effects of omega-3-acid ethyl esters capsules include:

- burping
- upset stomach
- a change in your sense of taste

These are not all the possible side effects of omega-3-acid ethyl esters capsules.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store omega-3-acid ethyl esters capsules?

- Store omega-3-acid ethyl esters capsules at room temperature, 59° to 86° F (15° to 30° C). Protect from light.
- Do not freeze omega-3-acid ethyl esters capsules.
- Safely throw away medicine that is out of date or no longer needed.

Keep omega-3-acid ethyl esters capsules and all medicines out of the reach of children.

General information about the safe and effective use of omega-3-acid ethyl esters capsules

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use omega-3-acid ethyl esters capsules for a condition for which it was not prescribed. Do not give omega-3-acid ethyl esters capsules to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about omega-3-acid ethyl esters capsules that is written for health professionals.

What are the ingredients in omega-3-acid ethyl esters capsules?

Active Ingredient: omega-3-acid ethyl esters, mostly EPA and DHA

Inactive Ingredients: alpha-tocopherol (in soybean oil), gelatin, glycerin, purified water and white ink. The capsule imprinting ink contains ammonium hydroxide, propylene glycol, shellac glaze, simethicone and titanium dioxide.

This patient labeling has been approved by the U.S. Food and Drug Administration.

APOTEX INC.

Omega-3-Acid Ethyl Esters Capsules, USP

1 gram

Manufactured in Canada for:

Apotex Corp.

Weston, FL. 33326 USA

Revision: 5

Revised: April 2019



OMEGA-3-ACID ETHYL ESTERS

omega-3-acid ethyl esters capsule, liquid filled

Product InformationProduct TypeHUMAN PRESCRIPTION
DRUGItem Code
(Source)NDC:55700-873(NDC:60505-
3170)Route of AdministrationORALV

Ingredient Name Basis of Strengt Streng Omega-3-Acid Ethyl Esters (UNII: D87YGH4Z0Q) (Omega-3 Fatty Acids - UNII: 71M78ENDSS) Omega-3-Acid Ethyl Esters 1 g I g I g I g I g Inactive Ingredient S Strengt I g I g I g I g ALPHATOCOPHEROL (UNII: HAN855PNZ1) I g I g GELATIN, UNSPECIFIED (UNII: EdG80N327L) I g I g GUYCERN (UNII: D059070X00R) I g I g AMMONIA (UNII: 5138019F1X) I g I g PROPYLENE GLYCOL (UNII: 6DC90167V3) I g I g SHELLAC (UNII: 15FIX9V2JP) I g I g Shape CAPSULE	_	ient/Active Moiety				
UNII: 71M78ENDSS) Inactive Ingredient Name in the steries in the s		Ingredient Name		Basis of Stre	ngth	Strength
Ingredient Name Strength .ALPHATOCOPHEROL (UNII: HAN855PNZ1)		hyl Esters (UNII: D87YGH4Z0Q) (Omega-3 Fatt	y Acids -		nyl	1 g
Ingredient Name Strength ALPHATOCOPHEROL (UNII: HAN855PNZ1) GELATIN, UNSPECIFIED (UMI: 2G86QN327L) GIYCERIN (UMI: PDC6A3C00X) <td>Inactive Ingr</td> <td>edients</td> <td></td> <td></td> <td></td> <td></td>	Inactive Ingr	edients				
ALPHATOCOPHEROL (UNII: H4N855PNZ 1) GELATIN, UNSPECIFIED (UNII: 2G86QN327L) GLYCERIN (UNII: PDC6A3C0OX) WATER (UNII: 0590F0KOR) AMMONIA (UNII: 5138019F1X) PROPYLENE GLYCOL (UNII: 6DC90167V3) SHELLAC (UNII: 46N107B710) DIMETHICONE (UNII: 2G80U4) TITANIUM DIOXIDE (UNII: 15F1X9V2)P) Product Characteristics COlor YELLOW (Light Yellow) Score no score Shape CAPSULE Size 22mm Flavor Characteristics Procees APSULE Size 22mm Flavor APO900 Contains Marketing Start Marketing End Date Date Size Size Size Size Size Size Size Siz					Strer	nath
GELATIN, UNSPECIFIED (UNII: 2G86QN327L) Image: Constant of the state of the	ALPHATOCOPH					5
GLYCERIN (UNII: PDC6A3COOX) Image: Comparison of the co						
water (UNII: 0590F0K00R) Image: Constraint of the second of the seco						
AMMONIA (UNII: 5138Q19F1X) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) SHELLAC (UNII: 46N107B710) DIMETHICONE (UNII: 22RU3N3Y10) SILICON DIOXIDE (UNII: 52FU3N3Y10) SILICON DIOXIDE (UNII: 15FJ726XBU4) TITANIUM DIOXIDE (UNII: 15FJX9V2JP) Product Characteristics CODE Product Characteristics CAPSULE Flavor CAPSULE Flavor Contains Product Product Marketing Start 01 NDC:55700-873- 120 in 1 BOTTLE; Type 0: Not a Combination 1 NDC:55700-873- 120 in 1 BOTTLE; Type 0: Not a Combination OT/02/2020 Marketing Start Marketing End Date Marketing End Marketing End Mar						
PROPYLENE GLYCOL (UNII: 6DC9Q167V3) Image: Constant of the state of the sta						
SHELLAC (UNII: 46N107B710) Image: Constant of the state of the						
DIMETHICONE (UNII: 92RU3N3Y10) SILICON DIOXIDE (UNII: ETJ7Z 6XBU4) TITANIUM DIOXIDE (UNII: 15FIX9V2JP) Product Characeristics Color V YELLOW (Light Yellow) Score no score CAPSULE CAPSULE 22mm Fiavor CAPSULE 22mm Contains CAPSULE 22mm Fiavor APO900 Contains CAPSULE 22mm Fiavor APO900 Contains CAPSULE CAPSU						
SILCON DIOXIDE (UNII: ETJ72 6X804) TITANIUM DIOXIDE (UNII: 15FIX9V2JP) Product Charsteristics Color YELLOW (Light Yellow) Score Size 22mm Bare CAPSULE CAPSULE Category Application Number or Monograph Marketing Start Marketing Start Marketing Start Marketing Start						
TITANIUM DIOXIDE (UNII: 15FIX9V2JP) Product Characteristics Color YELLOW (Light Yellow) Score no score Shape CAPSULE Size 22mm Flavor CAPSULE Size 22mm Color No score VELLOW (Light Yellow) Score no score Size 22mm Packaging Warketing Start APO900 V V Marketing Start Marketing End Date						
Product Characteristics Color YELLOW (Light Yellow) Score no score Shape CAPSULE Size 22mm Flavor APO900 Contains APO900 Packaging Marketing Start Marketing Start Marketing Start Marketing Information Marketing Information Number or Monograph Citation Marketing Start Date Marketing Start Date Marketing Start Date						
Color YELLOW (Light Yellow) Score no score Shape CAPSULE Size 22mm Havor Imprint Code AP0900 Color Package Description Marketing Start Date Marketing End Date NDC:55700-873- 120 in 1 BOTTLE; Type 0: Not a Combination Product 07/02/2020 Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing Start Date Marketing End Date						
Shape CAPSULE Size 22mm Flavor Imprint Code AP0900 Package Description Marketing Start Date Date Date Marketing Start Date I NDC:55700-873- 120 in 1 BOTTLE; Type 0: Not a Combination 01 Marketing Start Froduct Marketing Start Marketing Start Marketing Start Marketing Start Date Marketing Start Marketing Start Marketing Start Date Date	Product Char	acteristics				
Flavor Imprint Code AP0900 Contains Imprint Code AP0900 Package Description Marketing Start Date Marketing End Date 1 NDC:55700-873- 120 in 1 BOTTLE; Type 0: Not a Combination 01/02/2020 01/02/2020 Marketing Information Marketing Start Date Marketing Category Application Number or Monograph Citation Marketing Start Date	Color	YELLOW (Light Yellow)	Score		no sco	re
Interview of the second secon	-	CAPSULE	Size		22mm	
Marketing Start Date # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55700-873- 01 120 in 1 BOTTLE; Type 0: Not a Combination Product 07/02/2020 07/02/2020 Marketing Information Product Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date	Flavor		Imprint Cod	e	APO900	
Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55700-873- 01 120 in 1 BOTTLE; Type 0: Not a Combination Product 07/02/2020 07/02/2020 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing Start Date	Contains					
Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:55700-873- 01 120 in 1 BOTTLE; Type 0: Not a Combination Product 07/02/2020 07/02/2020 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing Start Date						
# Item Code Package Description Date Date 1 NDC:55700-873- 01 120 in 1 BOTTLE; Type 0: Not a Combination Product 07/02/2020 07/02/2020 Marketing Information Marketing Start Marketing End Date Marketing Category Application Number or Monograph Citation Marketing Start Marketing End Date	Packaging					
Image: Product On Product On Product Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date	# Item Code	Package Description		•		
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date	1		07/02/2020			
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date						
Category Citation Date Date	Marketing	Information				
ANDA ANDA090973 07/02/2020						
	ANDA	ANDA090973	07/02/202	0		

Labeler - Quality Care Products, LLC (831276758)

Establishment					
Name	Address	ID/FEI	Business Operations		
Quality Care Products, LLC		831276758	relabel(55700-873)		